Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Lixte Biotechnology Holdings Inc. shares valued at $49,000 were purchased by van der Baan Bastiaan Jeroen on Dec 30. At $4.90 per share, van der Baan Bastiaan Jeroen acquired 10,000 shares. The insider’s holdings grew to 10,000 shares worth approximately $9000.0 following the completion of this transaction.
Do You Know The Best Place To Find Gains In Volatile Markets?
In today's chaotic marketplace, the biggest gains will come from some currently-small companies that pass by older, larger businesses still stuck in a pre-pandemic world. The trick is figuring out which small caps will be tomorrow's winners. That's why StockWire News has put together a special Wealth Building Report, highlighting 3 small cap stocks set to soar in 2023.
Click here for full details and to join for free.
Sponsored
Also, Bernards Rene purchased 15,000 shares, netting a total of over 7,650 in proceeds. Following the buying of shares at $0.51 each, the insider now holds 150,000 shares.
Before that, Bernards Rene had added 10,000 shares to its account. In a trade valued at $6,100, the Director bought Lixte Biotechnology Holdings Inc. shares for $0.61 each. Upon closing the transaction, the insider’s holdings increased to 10,000 shares, worth approximately $0.12 million.
Analyzing LIXT Stock Performance
On Thursday, Lixte Biotechnology Holdings Inc. [NASDAQ: LIXT] rose 10.28% to $0.90. The stock’s lowest price that day was $0.80, but it reached a high of $0.97 in the same session. During the last five days, there has been a surge of approximately 1.25%. Over the course of the year, Lixte Biotechnology Holdings Inc. shares have jumped approximately 76.82%. Shares of the company reached a 52-week high of $2.7000 on 02/07/23 and a 52-week low of $0.4802 on 01/03/23. A 50-day SMA is recorded $0.7699, while a 200-day SMA reached $0.7102. Nevertheless, trading volume fell to 0.54 million shares from 0.23 million shares the previous day.
Support And Resistance Levels for Lixte Biotechnology Holdings Inc. (LIXT)
According to the 24-hour chart, there is a support level at 0.8100, which, if violated, would cause prices to drop to 0.7200. In the upper region, resistance lies at 0.9800. The next price resistance is at 1.0600. RSI (Relative Strength Index) is 49.13 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -0.1395, which suggests the price will decrease in the coming days. Percent R is at 87.00%, indicating bearish price movement. Stochastics %K at buying indicates that the stock is to be held.
Is Lixte Biotechnology Holdings Inc. subject to short interest?
Stocks of Lixte Biotechnology Holdings Inc. saw a sharp steep in short interest on Jan 30, 2023 dropping by 11500.0 shares to 27920.0. Data from Yahoo Finance shows that the short interest on Dec 29, 2022 was 39420.0 shares. A decline of -41.19% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 0.44 of the overall float, the days-to-cover ratio (short ratio) decline to 0.44.
Which companies own the most shares of Lixte Biotechnology Holdings Inc. (LIXT)?
According to Ethos Financial Group LLC filings, the company currently owns 248,084 shares, which is about 1.49% of the total LIXT shares outstanding. In its current portfolio, Geode Capital Management LLC holds 25,794 shares valued at $20377.0.